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ABSTRACT
Objectives: Our present study was done to understand molecular regulatory mechanisms of IQGAP proteins and their potentials as biomarker in 
pancreatic cancer.
Methods: In this review, relevant studies were obtained by assessing the PubMed database using the combination of words that included “IQGAP” 
and “pancreatic cancer”. 
Results: There is an increasing evidence showing that the expression of IQGAP1 and IQGAP3 is positively correlated with tumorigenesis; however, 
IQGAP2 might play a role to suppress tumor progression.
Conclusion: IQGAP proteins might have potentials as predictive and prognostic biomarker for human pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is one of the most lethal and frequently occurring 
malignancies in the world; it contributes to the 5-year prevalence of 99% 
in both males and females in Indonesia [1]. Pancreatic cancer is generally 
classified based on their cellular differentiation of the neoplastic cells 
and the macroscopic appearance of the tumor [2]. Pancreatic ductal 
adenocarcinoma is the most common types, contributing more than 
90% of all pancreatic malignancies [2,3]. The modifiable risk factors of 
pancreatic cancer include smoking, obesity, alcohol consumption, and 
dietary factors; meanwhile, diabetes mellitus, chronic pancreatitis, and 
genetic factors are among the non-modifiable risk factors [4]. Surgical 
resection, in combine with chemotherapy and radiotherapy, is the 
only possible treatment method by far; however, around 15–20% of 
patients who undergo surgical resection, the 5-year survival remains 
very low; it did not exceed more than 20% [3,5]. Moreover, only a 
minority of patients can undergo a curative operation after diagnosis, 
primarily because of unspecific symptoms and limitations in diagnostic 
methods [3,6,7]. In addition, targeted therapy using gemcitabine (GEM) 
in combination with erlotinib may only prolong survival rate on average 
2 weeks to several months [8–10]; however, increasing evidence of GEM 
and erlotinib resistance might limit the effect of this chemotherapy. 
In spite of finding effective curative method remains to be the major 
research focus, there is an increasing urgency to investigate detailed 
molecular mechanisms of cancer progression to elucidate novel 
biomarker in pancreatic cancer.
IQ-domain GTPase-activating proteins (IQGAPs) comprise a family 
of multidomain scaffold proteins that present in distinct organisms 
ranging from Saccharomyces cerevisiae and Caenorhabditis elegans to 
Xenopus laevis and mammals and regulate diverse biological processes 
including cell-cell adhesion, cell migration, extracellular signals, protein 
trafficking, and cytokinesis [11–14]. IQGAP1, a 190-kDa protein, was 
discovered in 1994 and most well studied among other IQGAPs 
recently [11,13,15]. IQGAP2 shares 62% similarities in the amino 
acid sequence with IQGAP1 [16]; meanwhile, IQGAP3 was identified 
back in 2007 [17]. The similarities in domain composition of IQGAPs 
might raise potentialities to share molecular functions among IQGAPs 
in some signaling pathways (Fig. 1); however, deregulation of IQGAPs 
might promote the development of various diseases [11]. In addition, 
there is a mounting evidence, suggesting an involvement of IQGAPs in 
human carcinogenesis in various types of cancer including ovarian [18], 
gastric [19], esophageal [20], liver [21–25], colorectal [26], breast [27], 
and prostate cancer [28]. Several studies have implicated that the 
presence of IQGAPs in pancreatic cancer is evident and might be 
correlated with tumorigenesis [29–37]. In this review, we focus on the 
molecular mechanisms of IQGAPs and their potentials as biomarker for 
early detection and prognostic evaluation in pancreatic cancer.
OVEREXPRESSION OF IQGAP1 AND IQGAP3 PROMOTE CELL 
MIGRATION AND INVASIONS IN PANCREATIC CANCER
In 2011, our understanding of human cancer reached a new milestone 
when Hanahan and Weinberg et al. proposed that cancer cells should 
display 10 fundamental traits in cellular physiology to be able to 
promote growth and metastatic dissemination, known as the hallmarks 
of cancer [38] (Fig. 2). Therefore, investigating molecular mechanism of 
IQGAPs based on these hallmarks is essential to better understand their 
role in pancreatic cancer.
As previously mentioned, IQGAP1 is the best-characterized protein 
among IQGAP isoforms. In physiological condition, IQGAP1 regulates 
cadherin-mediated focal adhesion, cell motility and migration, and 
endocytosis [39–41]. Moreover, the diverse range of protein-protein 
interactions suggests that IQGAP1 is highly influential in signal 
transduction pathways including mitogen-activated protein kinase 
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(MAPK) [41–46], receptor tyrosine kinases [27,47-49], receptor serine/
threonine kinases [50–52], and Wnt signaling pathways [53,54]. 
In vitro study using PANC-1 pancreatic ductal adenocarcinoma cell 
line shows that IQGAP1 binds with activated Rac1 that results in 
destabilization of E-cadherin-mediated adherens junctions, thus 
increase cell migration and invasion [36]. IQGAP1 was also reported to 
enhance cancer cell invasiveness by reducing cell-cell adhesion through 
an interaction with EGFP-MTA1 complex in the plasma membrane [34]. 
Using clinical samples of pancreatic carcinoma, Wang et al. also reported 
that the overexpression of IQGAP1 is obvious and associated with the 
grades of tumor differentiation [29]. Interestingly, the involvement of 
IQGAP1 in MAPK signaling cascade also reported to increase resistance 
to GEM [33].
Although less extensively studied, IQGAP3 was also reported to play a role 
in distinct cellular physiology; it was initially found to promote cell motility 
and migration by interaction with two Rho family GTPase proteins, Rac1 
and Cdc42 [17]. Furthermore, a study by Nojima et al. showed that IQGAP3 
is necessary to regulate normal cell proliferation through an interaction 
with ERK1 in Ras/ERK signaling cascade [55]. A comprehensive study 
by Xu et al. showed that increased expression of IQGAP3 was associated 
with larger tumor size, poorer differentiation, and increased incidence of 
metastasis; this could be due to decreased expression of E-cadherin, an 
important marker for epithelial-mesenchymal transition. Furthermore, 
siRNA-mediated knockdown of IQGAP3 increased the Caspase 3 and 
Caspase 9 level, indicating its relation with apoptosis regulation.
IQGAP2 AND ITS TUMOR SUPPRESSIVE POTENTIALS IN 
PANCREATIC CANCER
IQGAP2, first described in 1996, is predominantly expressed in the 
liver [11–13,23]. IQGAP2 was also reported to promote cell motility 
through binding to Rac1 and Cdc42 [12]. Furthermore, this protein is 
also found to regulate actin polymerization [56]. In addition, Schmidt 
et al. reported that IQGAP2 plays an important role in Wnt/β-catenin 
signaling pathway.
Unlike IQGAP1 and IQGAP3, several studies showed that IQGAP2 might 
eventually suppress tumor progression. Downregulated expression of 
IQGAP2 was evident in hepatocellular carcinoma; this phenomenon was 
linked to the modulation of Wnt/β-catenin pathways [21]. In addition, 
inactivation of IQGAP2 through promoter methylation was observed in 
gastric cancer, further leading to tumor progression and poor clinical 
outcome [19]. Moreover, forced expression of IQGAP2 significantly 
upregulates E-cadherin expression by suppressing AKT activation, thus 
hinder metastasis progression in prostate cancer [28].
The prognostic biomarker potential in pancreatic cancer was observed 
through a clinical study by Zeng et al. showing that the expression of 
IQGAP2 was associated with increased survival rates in pancreatic 
cancer patients who underwent radiotherapy [37]. Unfortunately, no 
more investigation about its tumor-suppressing ability in pancreatic 
cancer was published until recently. We propose that in vitro and in vivo 
study using IQGAP2 knockout mice might be necessary to confirm its 
role in pancreatic cancer.
CONCLUSION
Pancreatic cancer remains one of the deadliest malignancies in Indonesia 
and the world; therefore, seeking a new early diagnosis marker might 
Fig. 1: Schematic diagram of the IQ-domain GTPase-activating proteins (IQGAP) family. The domain structures and the amino acid 
homologies are shown. CHD, calponin homology domain; IQ repeats, IQGAP-specific repeats; IQ motif, a calmodulin-binding motif; GRD, 
RasGAP-related domains; RasGAP C, RasGAP C terminus. Adapted from Wang et al. [17]
Fig. 2: The hallmarks of cancer. Adapted from Hanahan and 
Weinberg [38]
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eventually decrease its mortality rate. IQGAP family proteins raised an 
intention in cancer research due to their role in tumorigenesis. While 
IQGAP1 remains the most well-characterized among IQGAPs, there 
is still less known about the detailed role of IQGAP2 and IQGAP3 in 
pancreatic cancer. IQGAPs share similar domain composition; however, 
their role is interestingly distinct. IQGAP1 and IQGAP3 promote tumor 
proliferation and invasiveness, but IQGAP2 acts as a tumor suppressor 
gene. Furthermore, the upregulated expression of IQGAP2 might result 
in better prognosis in clinical data. Nevertheless, investigating more 
specific mechanisms of IQGAP proteins, especially IQGAP2 and IQGAP3, 
are necessary to further clarify their potentials in pancreatic cancer.
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